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PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
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Humanized mouse models are useful tools
to understand pathophysiology and to
develop therapies for human diseases.
While significant progress has been made
in generating immunocompromised mice
with a human hematopoietic system, there
are still several shortcomings, one of
which is poor human myelopoiesis. Here,
we report that human CSF-1 knockin mice
show augmented frequencies and func-
tions of human myeloid cells. Insertion of
human CSF1 into the corresponding
mouse locus of Balb/c Rag2/ c/mice
through VELOCIGENE technology re-
sulted in faithful expression of human
CSF-1 in these mice both qualitatively
and quantitatively. Intra-hepatic transfer
of human fetal liver derived hematopoi-
etic stem and progenitor cells (CD34) in
humanized CSF-1 (CSF1h/h) newborn mice
resulted in more efficient differentiation
and enhanced frequencies of human
monocytes/macrophages in the bone mar-
row, spleens, peripheral blood, lungs, liver
and peritoneal cavity. Human monocytes/
macrophages obtained from the human-
ized CSF-1 mice show augmented func-
tional properties including migration,
phagocytosis, activation and responses
to LPS. Thus, humanized mice engi-
neered to express human cytokines will
significantly help to overcome the current
technical challenges in the field. In addi-
tion, humanized CSF-1 mice will be a
valuable experimental model to study hu-
man myeloid cell biology. (Blood. 2011;
118(11):3119-3128)
Introduction
The development of animal models to study human diseases has
significantly advanced our understanding of the underlying mecha-
nisms of several diseases, including cancer. To date, animal
models, particularly in the laboratory mouse, have proven to be
excellent candidates for the evaluation of the efficiency and
efficacy of drugs and therapy options. While the utilization of these
surrogate models to study human biology and diseases can be
largely justified, because of ethical and technical constrains on the
conduct of experimental therapies in humans, much study has
highlighted the potential limitations of extrapolating data from
mice to humans.1 It is increasingly evident that there are several
differences between the physiology of humans and mice and so,
therapies that have been proven successful in mice may not work
well in humans.
To overcome these issues, there has been a long-standing
interest in developing a “humanized mouse” model and intensive
work by several groups has successfully demonstrated the feasibil-
ity of studying human biology and diseases in mice. Since, a
functional and effective immune system in the recipient mouse will
result in the elimination of the transplanted tissues/cells of human
origin, use of genetic mutants that lack cells of the adaptive
immune system such as T, B, and NK cells has significantly
contributed to the success of the “humanized mouse” model.
Accordingly, the most effective candidates of humanized mouse
models include the NOD-SCID and the Balb/c strains that lack
genes including recombination activating genes (RAG), common 
chain (C), beta2 microglobin (B2M), and Perforin 1 (Prf1).2
Several studies over the past few decades have demonstrated the
feasibility of transplanting several types of human tissues, includ-
ing peripheral blood leukocytes, fetal liver cells, fetal bone, fetal
thymus, fetal lymph nodes, vascularized skin, artery segments, and
either mobilized or cord blood hematopoietic stem cells (HSCs),
into the humanized mice.3 This approach has been believed to
provide better model systems becausethe data obtained from
human cells in these mice might reflect the physiology of the
human system.
A major avenue of investigation in the field is to generate mice
with a complete hematopoietic system and a functional immune
system of the human origin. Interestingly, there has been much
progress in generating human T cells, B cells, NK cells, and DCs
from HSCs in humanized mice.2-9 In addition to the individual
hematopoietic compartment, injection of human HSCs in these
mice resulted in the reconstitution of lymphoid organs such as
thymus and spleen.2-9 Nevertheless, the frequencies of myeloid
cells, particularly granulocytes, macrophages, erythrocytes and
megakaryocytes, are very low a result that is probably because of
inefficient myelopoiesis from human HSCs in these mice.2,3 In
view of the fact that the cells of myeloid origin; erythrocytes,
megakaryocytes macrophages and granulocytes play vital func-
tions, such as oxygen transport, blood coagulation and develop-
ment of adaptive immune system, generating humanized mice with
efficient human myelopoiesis is of paramount importance.
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Colony stimulating factor-1 (CSF-1) or macrophage colony
stimulating factor (M-CSF) is one of the early cytokines that was
discovered to promote hematopoiesis. In the hematopoietic system,
CSF-1 is believed to act specifically on myeloid progenitors,
starting from the common myeloid progenitor (CMP) stage, and to
favor the differentiation of CMPs into the monocyte/macrophage
lineage.10 In addition, CSF-1 is necessary for the survival, adhesion
and motility of macrophages.11-13 CSF-1 signals through the CSF-1
receptor (Fms; CD115) and ligation of its receptor by CSF-1 results
in tyrosine phosphorylation of Fms and subsequent phosphoryla-
tion of several host cell proteins.11,13-15
Here, we hypothesized that the defective human myeloid
differentiation in the humanized mice might be because of the lack
of specific signals that promote myeloid differentiation. To validate
this, we engineered a new generation of humanized mice to secrete
human CSF-1 at physiologic levels from the appropriate tissues.
Analysis of these humanized CSF-1 mice revealed normal expres-
sion, both qualitatively and quantitatively, of human CSF-1.
Analysis of humanized CSF-1 mice engrafted with human CD34
cells indicated augmented frequencies of human monocytes/
macrophages in various tissues compared with the control mice.
Furthermore, human monocytes/macrophages obtained from these
mice exhibited enhanced functional properties over the macro-
phages that were obtained from control mice.
Methods
Human CSF1 knockin strategy
A targeting construct for replacing the mouse with the human CSF1 gene
(Velocigene Allele Identification Number 5093) in a single targeting step
was constructed using VELOCIGENE technology as described previ-
ously.16 Mouse and human CSF1 DNA were obtained from bacterial
artificial chromosome (BAC) RPCI-23, clone 373B18 and from BAC
RPCI-11, clone 101M23, respectively. In brief, a linearized targeting
construct generated by gap repair cloning containing mouse CSF1 upstream
and downstream homology arms flanking a 17.5 kb human CSF1 sequences
extending from exon 2 to 633nt downstream of noncoding exon 9, and a
floxed drug selection cassette was electroporated into RAG2/ c/
mouse embryonic stem (ES) cells, which was made from a commercially
available V17 ES cell line (BALB/c  129 F1). Mouse ES cells carrying a
heterozygous deletion of the Csf1 gene were identified by Loss-of-Allele
screening17 (with 2 TaqMan qPCR assays that recognized sequences in
intron 2 (TUF primer, 5-CCAGGAATGTCCACTATGGATTC-3; TUP
probe, 5ACTGCTCCTTGACCCTGCT
CTGACTCA-3; TUR primer, 5-TGGGCTGACTTCCCAAAGG-3)
and in the 3 flanking sequence (TDF primer, 5-TTAGGTGCTAGTAG-
GCTGGAAAGTG-3; TDP probe, 5-TGCAATCGCAGCTTCTCTCCT-
TACTAGGCT-3; TDR primer, 5-AATAGGAAGAACGAACAGGTCTA-
ATACC-3) of the mouse Csf1 gene. Simultaneous replacement of the
mouse gene with the human CSF1 gene was confirmed by Gain-of-Allele
TaqMan assays that detected one copy of a sequence in intron 2 of CSF1
(forward primer, 5-GCTGCTTGCCTGGGTTAGTG-3; probe, 5-TGC-
CCAGGAACATCAACCACTGATTCTG-3; reverse primer, 5-GAGGGA-
CAGCAGACCTCAGAAG-3) and one copy of the neomycin resistance
(neor) cassette (forward primer, 5-GGTGGAGAGGCTATTCGGC-3;
probe, 5TGGGCACAACAGACAATCGGCTG-3; reverse primer, 5-
GAACACGGCGGCATCAG-3; see supplemental Figure 1, available on
the Blood Web site; see the Supplemental Materials link at the top of the
online article). The qPCR assay that recognizes the CSF1 sequence does not
amplify DNA from the mouse genome. The same assays were used to
confirm the genotypes of mice derived from the targeted ES cells.
Cre-mediated excision of the drug selection cassette was confirmed with the
neor TaqMan assay. All primer-probe sets were supplied by Biosearch
Technologies (http://www.biosearchtech.com). Probes were labeled with
6-carboxy-fluorecein (FAM) on their 5 ends and BHQ-1 on their 3 ends.
Correctly targeted ES cells were further electroporated with a transient
Cre-expressing vector to remove the drug selection cassette. Targeted ES
cell clones without drug cassette were introduced into an 8-cell stage mouse
embryo by the VELOCIMOUSE method.18 VELOCIMICE (F0 mice fully
derived from the donor ES cell) bearing the humanized CSF1 gene (VG
5093) were identified by genotyping for loss of mouse allele and gain of
human allele using a modification of allele assay.16
Mice
Balb/c-Rag2/ c/ CSF1m/m, Balb/c-Rag2/ c/ CSF1h/m and Balb/
c-Rag2/ c/ CSF1h/h mice were kept under specific pathogen-free
conditions in the animal care facility at the Yale University. All mouse
experiments were approved by the Institutional Animal Care and Use
Committee of the Yale University.
CD34 cell isolation and transplantation
Human fetal liver samples were obtained from the human fetal liver tissue
repository at the Albert Einstein College of Medicine, Bronx, NY and from
Advanced Biosciences Resources Inc, Alameda, CA. All experiments
involving human tissues were performed under the approval of the Yale
Human Investigations Committee.
For isolating human CD34 cells, fetal liver samples were rinsed once
with PBS and cut into small pieces, treated with collagenase D (100ng/mL)
at 37°C for 45 minutes. Single cell suspensions were prepared and the
mononuclear cells were isolated using density gradient centrifugation
(Lymphocyte separation medium, MP biomedicals LLC). CD34 cells were
immuno-magnetically isolated with anti–human CD34 microbeads by MACS
technique according to manufacturer’s instructions (Miltenyi Biotech).
For transplantation, newborn mice (within day 1 of birth) were
sublethally irradiated with 2 separate doses (2  150 cGy) in a 4 hour
interval and 1-2  105 purified human CD34 cells in 20 uL of PBS were
injected into the liver using a 22-gauge needle (Hamilton Company).
Mesenchymal stroma cell isolation and culture
Long bones of mice were isolated and the BM cells were flushed out. Bones
were cut into pieces and digested with a cocktail of collagenase D and P
(25 ng/mL) for 45 minutes at 37°C. Suspension cells were isolated and
plated in the presence of mesenchymal stroma cell (MSC) culture medium
(StemCell Technologies). After 2 weeks of culture, adherent cells were
harvested, stained with cocktail of antibodies and CD45Sca1CD90
cells were sorted by Moflo high speed cell sorter (Beckman Coulter Inc).
These cells were further cultured in the presence of MSC culture medium
for 7 days.
Antibodies and flow cytometry
Single-cell suspensions were analyzed by flow cytometry using FACS
Calibur or LSRII and CellQuest software Version 7.5.4, FACS Diva
software Version 6.0 (all BD Biosciences) or FlowJo Version 6.3.2 software
(TreeStar Inc), respectively. Cell sorting of defined subpopulations was
performed using FACS Aria cell sorter (BD Biosciences). The following
anti–human antibodies were used in: CD11b, CD14, CD33, CD34, CD38,
CD40, CD45, CD80, CD86, CD90, and HLA-DR (BD Biosciences).
The following anti–mouse antibodies were used: CD11b, CD40, CD45,
CD80, CD86, F4/80, Gr1, H2Kd, and IAd (BD Biosciences).
Cell culture
For mouse macrophage differentiation, BM cells were plated in 6 well
plates in the presence of DMEM with 10% FCS, 2mM L-Glutamine, 1%
Penicillin-Streptomycin and 1mM nonessential amino acids. Cells were
treated with either recombinant murine CSF-1 (10 ng/mL) or recombinant
human CSF-1 (10 ng/mL) for 7 days. Cell culture supernatant was removed
every third day and culture was replaced with fresh medium and cytokines.
For human macrophage studies, such as activation, phagocytosis and
migration, 2  105 CD45CD14CD33 cells of the spleens were
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sorted and cultured in vitro in the DMEM with 15% human AB serum,
2mM L-Glutamine, 1% Penicillin-Streptomycin and 1mM nonessential
amino acids.
Activation, phagocytosis, and migration assays
For LPS stimulation in vivo, mice were injected intraperitoneally with LPS
(100 ng/g body weight). For LPS stimulation in vitro, LPS (10 ng/mL) was
added to the cells and cultured for either 1 or 2 days as mentioned in “Cell
culture.” For poly I:C stimulation in vitro, cells were cultured in the
presence of poly I:C (10 g/mL) for either 6 or 12 hours.
Phagocytosis assay was performed using the commercially available
Vybrant phagocytosis assay kit (Invitrogen) according to the manufactur-
er’s instructions.
Migration assays were performed using a commercially available QCM
chemotaxis cell migration assays kit (Millipore) according to the manufac-
turer’s instructions.
RNA extraction and real-time PCR
Total RNA was isolated using commercially available kit systems (RNeasy Mini
kit; QIAGEN). cDNAwas synthesised using oligo dT primer and expand reverse
transcriptase (Roche). The PCR reaction was performed in duplicates using 7500
real-time PCR systems and power SYBR Green PCR master mix (Applied
Biosystems) according to the manufacturer’s instructions using the following
gene specific primer pairs: Human CSF1 (sense: 5-TACTGTAGCCACATGAT-
TGGGA-3 and antisense: 5-CCTGTGTCAGTCAAAGGAAC-3), Mouse
csf1 (sense: 5-CGACATGGCTGGGCTCCC-3 and antisense: 5 -CGCATG-
GTCTCATCTATTAT-3), Human IFNa (sense:5-GTACTGCAGAATCTCTC-
CTTTCTCCTG-3 and antisense: 5-GTGTCTAGATCTGACAACCTCCCAG-
GCACA-3), Human IFNb (sense:5-TTGTGCTTCTCCACTACAGC-3 and
antisense: 5-CTGTAAGTCTGTTAATGAAG-3), Mouse hprt primers
(sense: 5-AAGGACCTCTCGAAGTGTTGGATA and antisense: 5-
CATTTAAAAGGAACTGTTGACAACG-3) and Human HPRT prim-
ers (sense: 5-CTTCCTCCTCCTGAGGAGTC-3 and antisense:
5-CCTGACCAAGGAAAGCAAAG-3).
ELISA
For cytokine quantification studies, either blood serum or cell culture
supernatants were collected and subjected to ELISA using commercially
available human CSF-1 (Ray Biotech Inc), human IL-6, and human TNF
ELISA kits (Ray Biotech Inc) according to the manufacturer’s instructions.
Histology
Solid organs were fixed in 4% PFA. Fixed organs were embedded in
paraffin (Blue RiBbon; Surgipath Medical Industries). Blocks were sec-
tioned and the 5-m sections were stained with H&E stain, followed by
placement of coverslips by routine methods. Sections were maintained
without any medium. Digital light microscopic images were recorded, at
room temperature, with a Zeiss Axio Imager.A1 microscope (with 2 and
10 objective lenses), AxioCam MRc5 camera, and AxioVision 4.7.1
imaging software (Carl Zeiss Microimaging LLC).
Statistical analysis
Data are presented as mean  SEM. Statistical significance was assessed
using a 2-sided Student t test. P values 	 .05 were considered to be
significant.
Results
Generation of humanized CSF-1 mice
The Balb/c strain with Rag2/ c/ deficiency serves as success-
ful model system for the study of the human immune system in
mice.8 To validate whether physiologic expression of human CSF-1
in a mouse results in improved differentiation of human macro-
phages in the humanized mice, we engineered the Balb/c Rag2/
c/ mice to express human CSF-1. To circumvent supra-
physiologic expression of human CSF-1 in these mice, we adopted
the strategy to replace the mouse csf1 gene with the human
counterpart. A construct (supplemental Figure 1) for replacing, in a
single targeting step, the mouse csf1 open reading frame with the
human CSF1 coding region (Velocigene Allele Identification
Number 5093), was constructed using the VELOCIGENE technol-
ogy as described previously.16 Of note, the promoter and other
regulatory elements (such as 5UTR) of the mouse were preserved
in this vector. The linearized targeting vector was electroporated
into the Balb/c  129 Rag 2/ c/. embryonic stem cells.
Correctly targeted ES cells were further electroporated with a
transient Cre-expressing vector to remove the drug selection
cassette. Targeted ES cell clones without drug cassette were
introduced into an 8-cell stage mouse embryo by the VELOCI-
MOUSE method.18 VELOCIMICE (F0 mice fully derived from the
donor ES cell) bearing the humanized CSF1 gene (VG 5093) were
identified by genotyping for the loss of the mouse allele and gain of
the human allele using a modification of allele assay.16 Through
sequential intercrossing of progenies, Balb/c Rag2/ c/ mice
chimeric mice and germ line transmitted mice with mouse and
human CSF-1 (CSF1h/m; heterozygous knockin) and human CSF-1
only (CSF1h/h; homozygous knockin) were generated.
Characterization of the humanized CSF-1 mice
First, we evaluated the expression of human CSF-1 in the
humanized CSF-1 mice. Organs from either CSF1m/m or CSF1h/h
mice were harvested and analyzed for murine and human CSF1
mRNA expression using primers that are species specific. As
shown in Figure 1A and B, CSF-1 is expressed in the majority of
the analyzed organs including BM, spleen, blood, liver, brain, lung,
testis, and kidney. However, thymus and skin did not show
detectable expression of CSF-1. Of note, the expression pattern of
mouse and human CSF-1 was comparable between CSF1m/m and
CSF1h/h mice, respectively. Next, we quantified the expression
levels of mouse and human CSF-1 in CSF1m/m, CSF1h/m and
CSF1h/h mice. BM mesenchymal stromal cells (MSCs) were
isolated and the expression levels of CSF-1 mRNA were quantified
using realtime-PCR (Figure 1C) and CSF-1 protein (secreted) was
quantified using ELISA (Figure 1D). As expected, CSF1m/m mice
expressed only mouse csf-1, CSF1h/m mice expressed both mouse
and human CSF-1 and CSF1h/h mice expressed only human CSF-1.
In addition, the expression level of human CSF-1 was comparable
with mouse csf-1. In line with these data, analysis of CSF-1 in
serum revealed comparable expression levels of CSF-1 protein in
m/m, h/m, and h/h mice (Figure 1E). Interestingly, hemizygocity
does not lead to decreased gene and protein expression levels,
indicating that gene-dosage levels seem not to be limiting for this
cytokine.
Earlier studies have documented that mice with defective
CSF-1 signaling (Csf1op/op and Csf1r/) exhibit tooth eruption
failure and bone defects.19-22 To investigate whether replacing
mouse Csf-1 with human CSF-1 results in deleterious effects,
especially on the bone and hematopoiesis, CSF1h/h mice were
analyzed at various ages. However, CSF1h/h mice revealed normal
teeth and bone properties (data not shown). Further, unlike the
Csf1op/op and Csf1r/ mice, the total cell content of the BM (Figure
2A), frequencies of myeloid cells in the BM, spleen (SP), and
peripheral blood (PB; Figure 2B) and the frequencies of macro-
phages in the BM and SP (Figure 2C) were comparable among the
CSF1m/m, CSF1h/m, and CSF1h/h mice, indicating that human CSF-1
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shows functional cross-reactivity to mouse cells. In line with
this observation, the cellular frequencies within the HSC
compartment (including long-term HSC; CD150CD48 LSK,
short-term HSCs; CD150CD48 LSK and multipotent progeni-
tors; CD150CD48 LSK) and myeloid progenitor compart-
ment (including common myeloid progenitors; Lineagec-
KitSca1CD34CD16/32, granulocyte monocyte progenitors;
Lineagec-KitSca1CD34CD16/32 and megakaryocyte
erythrocyte progenitors; Lineagec-KitSca1CD34CD16/
32) were comparable among the CSF1m/m, CSF1h/m, and
CSF1h/h mice (supplemental Figure 2).
A possible explanation for the normal hematopoiesis and bone
development in the CSF1h/h mice is likely that human CSF-1 is
cross reactive with mouse cells. Indeed, previous studies docu-
mented that human CSF-1 is active in mouse target cells, whereas
mouse CSF-1 is not cross active on human cells.23 To confirm this,
total BM cells from CSF1m/m were isolated and cultured in the
presence of either recombinant murine CSF-1 or recombinant
human CSF-1. Whereas BM cells cultured in the absence of
cytokine failed to survive, cells cultured in the presence of either
human or mouse CSF-1 showed comparable levels of in vitro
differentiation (Figure 2D). Analysis of these in vitro differentiated
macrophages for the expression of costimulatory molecules and
MHC indicated comparable levels of these molecules in the
presence of either human or mouse CSF-1 (Figure 2E).
Differentiation of human monocytes/macrophages in
humanized CSF-1 mice
To evaluate the impact of CSF-1 humanization, sublethally irradi-
ated newborn Rag2/ c/ CSF1m/m, Rag2/ c/ CSF1h/m,
and Rag2/ c/ CSF1h/h mice were transplanted intra-
hepatically (IH) with 
 2  105 purified human fetal liver CD34
cells. Recipients were bled at 8 weeks after transplantation to
confirm the cells of donor origin. 12 weeks after transplantation,
recipients were killed and their BM, SP, and PB were harvested.
Analysis of donor-derived hematopoiesis, based on human CD45
expression, revealed augmentation of human cell number in the
BM, spleen, and blood of humanized CSF-1 (h/m and h/h) mice
over CSF1m/m mice (supplemental Figure 3). As expected the relative
and absolute frequencies of CD14CD33 monocyte/macrophage
lineage cells were increased in the BM, SP, and PB of both CSF1h/m and
CSF1h/h mice compared with CSF1m/m mice (Figure 3A-C). Although
CSF1h/m mice exhibited increased frequencies of CD14CD33 cells,
the maximum frequencies of CD14CD33 cells were found in the
CSF1h/h mice. Interestingly, in addition to this increase, the frequencies
of CD14CD33 cells were also increased in the BM, SP, and PB of
CSF1h/m and CSF1h/h mice (Figure 3A). Nevertheless, the frequencies of
human erythro-mekaryocyte lineage and lymphoid lineage cells re-
mained comparable among CSF1m/m, CSF1h/m, and CSF1h/h mice
(supplemental Figure 4).
Figure 1. Expression of human CSF-1 in the humanized CSF-1 mice. (A) Indicated organs from CSF1m/m and CSF1h/h were isolated, RNA was extracted- and reverse
transcription (RT)–PCR analysis was performed either using mouse CSF-1 (top) or human CSF-1 (middle) specific primers. HPRT levels (bottom) was used as controls for the
input cDNA. Data are representative of 2 independent experiments. (B) Indicated organs from CSF1h/m were isolated, RNA was extracted and RT-PCR analysis was performed
either using mouse CSF-1 (top) or human CSF-1 (bottom) specific primers. RNA extracted either from mouse liver or human fetal liver served as positive controls for mouse and
human primer pairs, respectively, no RT, and no template PCR reactions served as negative controls. Data are representative of 2 independent experiments. (C) Bone
Associated Stromal Cells from CSF1m/m, CSF1h/m, and CSF1h/h mice were isolated and cultured in vitro for 10 days. Cells were lysed, RNA was extracted, and real-time PCR
analysis was performed using either mouse CSF-1 (white) or human CSF-1 (black) specific primers. Shown are the mean values of duplicate samples. Error bars
indicate  SEM. Input cDNA quantity was normalized according to HPRT (hypoxanthine guanine phosphoribosyl transferase) expression levels. Data are representative of 2
independent experiments. (D) Bone Associated Stromal Cells from CSF1m/m, CSF1h/m, and CSF1h/h mice were isolated and cultured in vitro for 10 days. Cell culture
supernatants were collected and the secreted levels of mouse (white) and human (black) CSF-1 were quantified using species specific CSF-1 ELISA kits. Shown are the mean
values of triplicate samples. Error bars indicate  SEM. Data are representative of 2 independent experiments. (E) CSF1m/m, CSF1h/m, and CSF1h/h mice were bled and the
serum levels of human and mouse CSF-1 were quantified through ELISA. Shown are the mean values of triplicate samples. Error bars indicate  SEM.
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To analyze whether human CSF-1 knockin mice support
sustained human myelopoiesis, recipients were analyzed at 12,
16, and 20 weeks after transplantation. While human CD14CD33
monocyte/macrophage lineage cells were slightly reduced at 16 weeks
and highly reduced after 20 weeks of transplantation in the CSF1m/m
mice, significant proportions of human CD14CD33 cells were
observed in both CSF1h/m and CSF1h/h mice at even 16 and 20 weeks.
The maximum frequencies of human CD14CD33 cells were seen in
the CSF1h/h mice (Figure 4A-B).
Next, we assessed whether the humanized CSF-1 mice support
efficient differentiation of human tissue macrophages. To this end,
CSF1m/m, CSF1h/m, and CSF1h/h mice were perfused with PBS and
their organs including liver, lungs and skin were harvested. Cells of
the peritoneum were obtained by flushing the peritoneal cavity with
PBS. Single cell suspensions were prepared and the frequencies of
human CD14CD33 cells were calculated. As expected, the
frequencies of human CD14CD33 cells were significantly
increased in the liver, lungs and peritoneum of both CSF1h/m and
CSF1h/h mice. However, analysis of skin explants revealed compa-
rable frequencies of human CD14CD33 cells between CSF1m/m
and CSF1h/m mice, although a significant increase of these cells was
observed in the skin explants of CSF1h/h mice (Figure 5). Of note,
expression of human CSF-1 in mice did not substantially affect the
murine microenvironment of organs including spleen, liver and
lungs as indicated by similar organ architecture (supplemental
Figure 5). Taken together these data demonstrate that expression of
human CSF-1 in mice improves myeloid/macrophage lineage
differentiation of human hematopoietic stem and progenitors cells.
Functions of human monocytes/macrophages in the
humanized CSF-1 mice
To investigate whether the human CD14CD33 monocytes/
macrophages in the humanized CSF-1 mice functioned normally,
both in vivo and in vitro functional studies were performed.
Sublethally irradiated CSF1m/m and CSF1h/m newborn mice were
injected with human fetal liver CD34 cells and 12 weeks after
transplantation, donor derived hematopoiesis was assessed and the
recipient mice were injected with either LPS or PBS. Two days
after LPS injection, recipients were analyzed for the frequencies of
human CD14CD33 cells in the spleen. While LPS injection
induced only a modest increase of human monocyte/macrophage
lineage cells in the CSF1m/m mice, compared with the PBS injected
groups, LPS injected CSF1h/m mice showed a several fold increase
of human CD14CD33 cells in the spleen (Figure 6A). Next we
determined the ability of these cells to produce pro-inflammatory
cytokines in response to LPS stimulation in vivo. CSF1m/m and
CSF1h/m mice engrafted with human CD34 cells were injected
with LPS and 6 hours after injection, mice were bled and the serum
levels of human and mouse IL-6 and TNF were determined by
Figure 2. Myeloid differentiation in the humanized CSF-1 mice and cross-reactivity of human CSF-1. (A) Absolute numbers of BM cells of CSF1m/m, CSF1h/m, and
CSF1h/h mice, as average per animal (2 tibia and fibula), were determined. Each group contains n  5 mice, age 4 weeks. Error bars indicate  SEM. Data are representative
of 3 independent experiments. (B) Single-cell suspension of BM (top), spleen (middle), and peripheral blood (PB) from CSF1m/m, CSF1h/m, and CSF1h/h mice were prepared,
stained with Gr1 and CD11b antibodies, and analyzed by flow cytometry. (C) Single-cell suspension of BM (top) and spleen (middle) from CSF1m/m, CSF1h/m, and CSF1h/h mice
were prepared, stained with F4/80 and CD11b antibodies, and analyzed by flow cytometry. (D) BM cells were isolated and cultured in the presence of either recombinant mouse
CSF-1 (left) or human CSF-1 (right) for 7 days. Cells were stained with F4/80 and CD11b antibodies and analyzed by flow cytometry. (E) BM cells were isolated and cultured in
the presence of either recombinant mouse CSF-1 (filled) or human CSF-1 (open) for 7 days. Cells were stained with indicated surface markers and analyzed by flow cytometry.
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ELISA. Consistent with the increased frequencies of monocytes/
macrophages in the humanized CSF-1 mice, elevated levels of
human IL-6 and human-TNF, but not mouse IL-6 and mouse
TNF, were detected in the CSF1h/m mice. Although the basal
levels of these cytokines were higher in the CSF1h/m mice, LPS
stimulation resulted in augmented levels of human IL-6 and human
Figure 3. Human myeloid differentiation in the humanized CSF-1 mice. (A) Single-cell suspension of BM (top), spleen (middle), and peripheral blood (PB) from human
CD34 cells engrafted CSF1m/m, CSF1h/m, and CSF1h/h mice were prepared, stained with CD45, CD14, and CD33 human antibodies, and analyzed by flow cytometry. Cells
that are human CD45 were pregated and discriminated based on CD14 and CD33 expression. (B-C) Percentages (B) and absolute numbers (C) of human CD45
CD14CD33 cells of BM (top), spleen (middle), and peripheral blood (PB) were calculated. Absolute numbers of BM cells were determined as average per animal (2 tibia and
fibula) and of peripheral blood were determined per milliliter volume of blood. Each group contains n  20 mice. Each symbol represents an individual mouse; horizontal bars
indicate the mean values. Data are representative of 5 independent experiments.
Figure 4. Sustained human myeloid differentiation in the humanized CSF-1 mice. (A) Human CD34 cells engrafted CSF1m/m, CSF1h/m, and CSF1h/h mice were bled after
12, 16, and 20 weeks of transplantation. Cells were stained with CD45, CD14, and CD33 human antibodies, and analyzed by flow cytometry. Cells that are human
CD45 were pregated and discriminated based on CD14 and CD33 expression. (B) Relative frequencies of human CD45 CD14CD33 cells were plotted. Each group
contains n  10 mice. Each symbol represents an individual mouse; horizontal bars indicate the mean values. Data are representative of 3 independent experiments.
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TNF in the serum (Figure 6B-C), most likely, because of
increased numbers of human monocytes/macrophages in CSF1h/m
mice over CSF1m/m mice. We also analyzed the capacity of
monocytes/macrophages, obtained from humanized CSF-1 mice,
to secrete pro-inflammatory cytokines in vitro. Human
CD14CD33 cells were isolated from the spleens of either
CSF1m/m or CSF1h/h mice, after 12 weeks of reconstitution with
human CD34 cells, and stimulated with LPS in vitro for either
24 or 48 hours. The levels of human IL-6 and TNF cytokines in
the cell culture supernatants were assessed by ELISA.
CD14CD33 cells purified from CSF1h/h mice secreted aug-
mented levels of these cytokines in response to LPS, similar as
human fetal liver cell derived cells (Figure 7A-B). Similarly,
human CD14CD33 cells isolated from the humanized CSF-1
mice expressed augmented levels of IFN- and IFN- mRNA in
response to poly I:C stimulation (Figure 7C). Finally, we analyzed
the phagocytic, migratory and activation properties of human
monocytes/macrophages obtained from the humanized CSF-1
mice. Human CD14CD33 cells purified from human CD34
reconstituted, CSF1h/h mice exhibited increased phagocytosis (Fig-
ure 7D) and displayed enhanced chemotaxis in response to the
chemokine Mip3 (Figure 7E). In addition, human monocytes/
macrophages obtained from the CSF1h/h mice displayed enhanced
activation properties as assessed based on up-regulation of costimu-
latory molecules including CD40, CD80 and CD86, and HLA-DR
in response to LPS stimulation in vitro (Figure 7F). Overall,
besides increased quantity, human monocytes/macrophages differ-
entiated in the presence of human CSF-1 in the humanized mice
exhibit also augmented qualitative, functional properties.
Discussion
In the present study we documented that replacing the mouse
CSF-1 gene with its human counterpart results in efficient human
macrophage differentiation in mice that were reconstituted with
human hematopoietic stem and progenitor cells. Generating a
mouse with a completely reconstituted and functional hematopoietic/
immune system of human origin has been a great challenge in the
field. To date, 3 mouse strains (NOD-scid c/, [NSG], NOD/Shi-
scid c/ [NOG], and Balb/c-Rag2/ c/) have proved to be
useful candidates for the reconstitution of human hematopoietic
system in mice. Despite the advantages conferred by each of these
strains, there are several bottlenecks that need to be addressed to
optimize the human immune system in mice. The current chal-
lenges in using these models include (1) a high degree of variability
of the human chimerism within the individual engrafted groups, (2) lack
of sustained human hematopoiesis (after 5 months of transplantation),
(3) poor or absent development of secondary lymphoid organs (espe-
cially peripheral lymph nodes), (4) suboptimal lymphocyte reconstitu-
tion (mainly B and T cells), (5) highly reduced myelopoiesis (including
granulocytes and macrophages), and (6) almost complete absence of
erythrocyte and megakaryocyte differentiation. While efforts have been
taken by several investigators to overcome these technical hurdles, the
success of using xenogenic models to study human biology is far from
being complete.
Our conviction has been that one of the prime reasons for the
lack of complete human hematopoiesis in mice might be the
deficiency of the microenvironments that support human hemato-
poiesis in mice.6,24 Whereas many of the human cytokines have
proven to be cross reactive with murine receptors, unfortunately,
many of the murine hematopoietic cytokines are not cross reactive
with human cells. We hypothesized that this is one of the major
reasons for the poor reconstitution of human myeloid cells in the
humanized mice models. In an attempt to overcome this major
technical challenge, we reasoned that incorporating the human
CSF-1 gene in the Balb/c-Rag2/ c/ mice might improve
myeloid reconstitution, particularly the monocyte/macrophage lin-
eage, because CSF-1 is an indispensable cytokine for the differen-
tiation of macrophages.10,11,13,14,25 Analysis of the humanized
CSF-1 mice indicated efficient differentiation of human monocytes/
macrophages in the BM, spleen and peripheral blood. Moreover,
we could detect human macrophages in several different tissues
including, lungs and liver, in these mice suggesting that the
presence of CSF-1 in humanized mice is sufficient to promote the
differentiation of human tissue macrophages. Intriguingly, our
functional studies involving the human monocytes/macrophages,
isolated from the CSF1m/m and the CSF1h/h mice suggest that cells
Figure 5. Frequencies of tissue-derived human mono-
cytes/macrophages in the humanized CSF-1 mice.
CSF1m/m, CSF1h/m, and CSF1h/h mice were engrafted
with human CD34 cells, and 12 weeks after transplanta-
tion, mice were killed perfused with PBS. Liver (A), lungs
(B), and skin (C) were harvested and single-cell suspen-
sions were prepared. Peritoneal cavity cells (D) were
collected by aspirating with PBS. Cells were stained with
human CD45, CD14, and CD33 antibodies, and analyzed
by flow cytometry. Each symbol represents an individual
mouse; horizontal bars indicate the mean values. Data
are representative of 3 independent experiments.
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from the CSF1h/h mice were better in performing functions such
as phagocytosis, migration, activation and cytokine secretion.
Based on these findings, it might be inferred that monocytes/
macrophages that differentiate in the presence of human CSF-1
might function better. In line with our observations, it has been
shown that CSF-1 is not only responsible for the differentiation
of HSC into macrophage lineage cells, but also for the proper
functions of macrophages, because constant signaling mediated
through CSF-1/CSF-1R is necessary for protein synthesis in
macrophages.11
In the present study, we adopted the VELOCIGENE technol-
ogy16 to generate a novel line of Balb/c-Rag2/ c/ mice that
express human CSF-1. Accordingly, the mouse CSF-1 coding
region was replaced with the human counterpart without disturbing
the regulatory elements, such as the promoter, of the mouse csf1
gene. This results in a chimeric gene that contains the mouse
regulatory elements and the human CSF-1 coding region. Our
expression studies indicated that this chimeric gene is expressed
faithfully in both a qualitative and quantitative manner. While we
were about to complete our studies on the CSF1h/h mice, a report
from the Chen group has documented that transient expression of
human CSF-1 in mice results in enhanced reconstitution of human
macrophages in the NOD-scid c/ mice.26 In their study, the
authors had followed the “hydrodynamic tail vein injection” approach to
express human CSF-1 in their mice. While this is an interesting and a
rapid approach to express transgenes (such as human cytokines) in mice,
it has several technical limitations as follows: (1) only short-term
expression of transgenes (usually 2-3 weeks), (2) expression levels of
transgene are nonphysiologic, (3) inconsistent levels of transgene
expression within experimental groups, and (4) the expression of
transgene occurs predominantly in the liver and not in the other tissues.
The knockin strategy described in our study overcomes all the above
technical limitations.
The role of CSF-1 in the differentiation of mouse macrophages
has been well established. Mice that are deficient for either CSF-1
(Csf1op/op) or its receptor (Csf1r/) exhibit severe reduction in
macrophage and osteoclast frequencies, osteopetrosis, tooth erup-
tion failure, developmental defects in various tissues, including
nervous system, male and female fertility, the dermis and
synovial membranes.19-22,27-29 While these studies have provided
very important insights into the roles of CSF-1 in various mouse
tissues the significance of CSF-1 in human hematopoiesis remains
Figure 6. LPS response in vivo. (A) CSF1m/m and CSF1h/m mice were engrafted with human CD34 cells, and 12 weeks after transplantation LPS was injected
intraperitoneally. Forty-eight hours later mice were killed and the frequencies of human CD45CD14CD33 cells in the spleen were determined. PBS-injected mice served as
controls. Each symbol represents an individual mouse; horizontal bars indicate the mean values. (B-C) CSF1m/m and CSF1h/m mice were engrafted with human CD34 cells,
and 12 weeks after transplantation LPS was injected intraperitoneally. Six hours later mice were bled and the serum levels of human (right) and mouse (left) IL-6 and TNF
were quantified through ELISA. PBS-injected mice served as controls. Shown are the mean values of triplicate samples. Error bars indicate  SEM.
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largely unknown. This is because of obvious ethical and technical
difficulties in using human subjects for studying human biology. In
this regard, our mice that are engineered to express human
cytokines, will serve as valuable tools, because this approach
not only improves the reconstitution of human hematopoietic
cells in the humanized mice, but also enables improved under-
standing of the physiology and functions of cytokines in human
hematopoiesis. Thus, the current approach involving the CSF1h/h
mice model serves as a “gain of function” study to highlight the
importance of CSF-1 in the development and functions of
human macrophages. In essence, these findings provide further
proof of principle that genetic manipulation of the existing
humanized mouse models will significantly improve the overall
engraftment of human tissues and will prove to be valuable tools
in understanding the pathophysiology and in the treatment of
several human disorders and diseases.
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